Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Embla Medical hf Management

Management Kriterienprüfungen 3/4

Embla Medical hf's CEO ist Sveinn Solvason, ernannt in Apr 2022, hat eine Amtszeit von 2.08 Jahren. Die jährliche Gesamtvergütung beträgt $1.18M, bestehend aus 48.8% Gehalt und 51.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.016% der Aktien des Unternehmens, im Wert von DKK1.95M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.1 Jahre bzw. 15.3 Jahre.

Wichtige Informationen

Sveinn Solvason

Geschäftsführender

US$1.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	48.8%
Amtszeit als Geschäftsführer	2.2yrs
Eigentum des Geschäftsführers	0.02%
Durchschnittliche Amtszeit des Managements	2.2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	15.4yrs

Jüngste Management Updates

Recent updates

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

May 14

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 26

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

Dec 22

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Dec 07

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Sep 21

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Sep 02

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Aug 16

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Jun 16

Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Jun 01

Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

May 08

Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Feb 22

Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report

Feb 03

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Nov 25

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Oct 17

Is Össur hf (CPH:OSSR) A Risky Investment?

Sep 28

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Aug 21

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Jul 11

Here's Why Össur hf (CPH:OSSR) Can Manage Its Debt Responsibly

May 28

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

May 07

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Mar 25

We Think The Compensation For Össur hf.'s (CPH:OSSR) CEO Looks About Right

Mar 02

We Think Össur hf (CPH:OSSR) Can Stay On Top Of Its Debt

Feb 22

Does The Market Have A Low Tolerance For Össur hf.'s (CPH:OSSR) Mixed Fundamentals?

Feb 09

What Kind Of Shareholders Own Össur hf. (CPH:OSSR)?

Jan 26

Össur hf (CPH:OSSR) Shareholders Have Enjoyed An Impressive 115% Share Price Gain

Jan 08

We're Watching These Trends At Össur hf (CPH:OSSR)

Dec 21

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Sveinn Solvason im Vergleich zu den Einnahmen von Embla Medical hf verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	US$57m
Dec 31 2023	US$1m	US$576k	US$58m
Sep 30 2023	n/a	n/a	US$52m
Jun 30 2023	n/a	n/a	US$45m
Mar 31 2023	n/a	n/a	US$43m
Dec 31 2022	US$780k	US$409k	US$43m

Vergütung im Vergleich zum Markt: SveinnDie Gesamtvergütung ($USD1.18M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Danish ($USD1.61M).

Entschädigung vs. Einkommen: SveinnDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.

Geschäftsführer

Sveinn Solvason (46 yo)

2.2yrs

Amtszeit

US$1,180,000

Vergütung

Mr. Sveinn Solvason had been Chief Financial Officer of Embla Medical hf. (formerly known as ssur hf.) since May 2013 until April 1, 2022 and serves as its President & CEO since April 1, 2022.Mr. Solvaso...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Sveinn Solvason	President & CEO	2.2yrs	US$1.18m	0.016% $ 1.9m
Ossur Kristinsson	Founder	no data	US$25.00k	keine Daten
Gudny Sveinsdottir	Chief Financial Officer	1.8yrs	keine Daten	keine Daten
Lukas Marklin	Chief Operating Officer	less than a year	keine Daten	keine Daten
Edda Luovigsdottir	Investor Relations Director	no data	keine Daten	keine Daten
Margret Fridriksdottir	Executive Vice President of People	no data	US$242.00k	0.0083% $ 987.5k
Olafur Gylfason	Chief Commercial Officer	no data	US$600.00k	0.0030% $ 357.3k
Gudjon Karason	Executive Vice President of EMEA & APAC	6.6yrs	keine Daten	0.023% $ 2.7m
Christian Robinson	President of Americas	no data	keine Daten	0.0031% $ 368.1k
Hildur Einarsdottir	Executive Vice President of Research & Development	2.2yrs	keine Daten	0.00014% $ 16.7k

2.2yrs

Durchschnittliche Betriebszugehörigkeit

50yo

Durchschnittliches Alter

Erfahrenes Management: EMBLADas Führungsteam des Unternehmens gilt als erfahren (2.1 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Niels Jacobsen	Chairman of the Board	19.4yrs	US$108.00k	0.048% $ 5.7m
Svafa Gronfeldt	Vice Chairman of the Board	16.4yrs	US$72.00k	keine Daten
Gudbjorg Eggertsdottir	Independent Director	11.3yrs	US$43.00k	0.0062% $ 733.7k
Arne Nielsen	Director	15.4yrs	US$50.00k	keine Daten
Alberto Esquenazi	Independent Director	3.3yrs	US$43.00k	keine Daten

15.4yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: EMBLADie Vorstandsmitglieder sind sehr erfahren ( 15.3 ).

Embla Medical hf Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Össur hf., Annual General Meeting, Mar 12, 2025

Össur hf. Announces Executive Changes

Less than half of directors are independent

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Less than half of directors are independent

Recent updates

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

New minor risk - Financial position

A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)

Is Össur hf (CPH:OSSR) Using Too Much Debt?

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Investor sentiment improves as stock rises 15%

Full year 2023 earnings: EPS misses analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2024

Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E

Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Össur hf., Annual General Meeting, Mar 12, 2025

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Third quarter 2023 earnings released: EPS: US$0.033 (vs US$0.016 in 3Q 2022)

Össur hf. Reaffirms Financial Guidance for the Year 2023

A Look At The Fair Value Of Össur hf. (CPH:OSSR)

We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Second quarter 2023 earnings: EPS misses analyst expectations

Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital

Össur hf. Announces Executive Changes

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

First quarter 2023 earnings released: EPS: US$0.024 (vs US$0.022 in 1Q 2022)

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Consensus EPS estimates fall by 12%

Full year 2022 earnings: Revenues in line with analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2023

A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2023 Results on Apr 25, 2023

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Less than half of directors are independent

Consensus EPS estimates fall by 23%

Third quarter 2022 earnings released: EPS: US$0.016 (vs US$0.041 in 3Q 2021)

Investor sentiment improved over the past week

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Össur hf. (CPSE:OSSR) acquired Naked Prosthetics.

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Second quarter 2022 earnings released: EPS: US$0.034 (vs US$0.046 in 2Q 2021)

Price target decreased to kr.42.00

Össur hf. Revises Earnings Guidance for the Year 2022

Össur hf. Reports Preliminary Earnings Results for the Second Quarter and First Half of 2022

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Price target decreased to kr.43.70

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Now 22% undervalued after recent price drop

Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

Now 20% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Össur Hf. Announces New R&D Leadership

Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Össur Launches New POWER KNEE

Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report

Full year 2021 earnings: EPS misses analyst expectations

Össur hf. Announces Sales Guidance for the Full Year 2022

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.035 in 3Q 2020)

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Is Össur hf (CPH:OSSR) A Risky Investment?

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Össur Hf. Announces Earnings Guidance for the Full Year 2021

Second quarter 2021 earnings released: EPS US$0.046 (vs US$0.042 loss in 2Q 2020)

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively